PL3310347T3 - Długo działające czynniki krzepnięcia i sposoby wytwarzania - Google Patents

Długo działające czynniki krzepnięcia i sposoby wytwarzania

Info

Publication number
PL3310347T3
PL3310347T3 PL16811146T PL16811146T PL3310347T3 PL 3310347 T3 PL3310347 T3 PL 3310347T3 PL 16811146 T PL16811146 T PL 16811146T PL 16811146 T PL16811146 T PL 16811146T PL 3310347 T3 PL3310347 T3 PL 3310347T3
Authority
PL
Poland
Prior art keywords
methods
long
coagulation factors
producing same
acting coagulation
Prior art date
Application number
PL16811146T
Other languages
English (en)
Inventor
Udi Eyal Fima
Gili Hart
Original Assignee
Opko Biologics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd. filed Critical Opko Biologics Ltd.
Publication of PL3310347T3 publication Critical patent/PL3310347T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL16811146T 2015-06-19 2016-06-19 Długo działające czynniki krzepnięcia i sposoby wytwarzania PL3310347T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182370P 2015-06-19 2015-06-19
PCT/IL2016/050645 WO2016203482A2 (en) 2015-06-19 2016-06-19 Long-acting coagulation factors and methods of producing same
EP16811146.6A EP3310347B1 (en) 2015-06-19 2016-06-19 Long-acting coagulation factors and methods of producing same

Publications (1)

Publication Number Publication Date
PL3310347T3 true PL3310347T3 (pl) 2021-12-27

Family

ID=57545347

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16811146T PL3310347T3 (pl) 2015-06-19 2016-06-19 Długo działające czynniki krzepnięcia i sposoby wytwarzania

Country Status (12)

Country Link
US (2) US10960058B2 (pl)
EP (2) EP3988113A1 (pl)
JP (3) JP7096668B2 (pl)
KR (3) KR102172937B1 (pl)
CN (2) CN113289009B (pl)
AU (3) AU2016280867B2 (pl)
CA (2) CA2989990C (pl)
ES (1) ES2893616T3 (pl)
HU (1) HUE055449T2 (pl)
IL (3) IL301728A (pl)
PL (1) PL3310347T3 (pl)
WO (1) WO2016203482A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3230309B1 (en) * 2014-12-10 2023-03-29 OPKO Biologics Ltd. Methods of producing long acting ctp-modified growth hormone polypeptides
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN113336831A (zh) * 2020-07-24 2021-09-03 上海延立药业有限公司 一种用于开发新冠病毒疫苗的长效重组糖蛋白
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
CN116148456B (zh) * 2023-02-23 2023-09-15 珠海美华医疗科技有限公司 聚茴香脑磺酸钠抗凝血效价的检测方法及应用

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4911691A (en) 1984-09-21 1990-03-27 Menlo Care, Inc. Assembly for adminstering IV solution
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1989010756A1 (fr) 1988-05-06 1989-11-16 Toray Industries, Inc. COMPOSITION D'INTERFERON beta STABLE
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5792460A (en) 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US5338835A (en) 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5705478A (en) 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US6028177A (en) 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
DE69422169D1 (de) 1993-04-20 2000-01-20 Univ St Louis Modifizierte proteine und peptide enthaltende pharmazeutische mittel
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
BR9506313A (pt) 1994-08-12 1997-08-05 Univ Washington Formas de cadeia simples do quarteto de hormônio de glicoproteína
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6103501A (en) 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
ES2244438T3 (es) 1999-05-24 2005-12-16 Mitsubishi Pharma Corporation Compuestos de fenoxipropilamina.
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
AU2001233299A1 (en) 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US20030036181A1 (en) 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
CN1507357A (zh) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
BR0115257A (pt) 2000-11-10 2003-08-12 Proteopharma Aps Análogos de apolipoproteìna
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
JP4409135B2 (ja) 2000-12-01 2010-02-03 武田薬品工業株式会社 生理活性物質含有製剤の製造法
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
KR101229995B1 (ko) 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
EP1342730B1 (en) 2000-12-11 2006-03-15 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP5160005B2 (ja) 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
US6987172B2 (en) 2001-03-05 2006-01-17 Washington University In St. Louis Multifunctional single chain glycoprotein hormones comprising three or more β subunits
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CN1512890A (zh) 2001-04-25 2004-07-14 开米卡公司 Hcg制剂
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
ATE542904T1 (de) 2001-10-29 2012-02-15 Crucell Holland Bv Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
KR100511749B1 (ko) 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
KR100467750B1 (ko) 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100467751B1 (ko) 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
GB0206048D0 (en) 2002-03-14 2002-04-24 Croda Int Plc Use
US20040009902A1 (en) 2002-05-13 2004-01-15 Irving Boime CTP extended erythropoietin
US20070298041A1 (en) 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
NZ538217A (en) 2002-07-17 2007-04-27 Biogen Idec Inc Beta interferon when used to treat proteinuria, glomerular cell proliferation and inflammation
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
RU2357750C2 (ru) 2002-12-31 2009-06-10 Элтус Фармасьютикалз Инк. Кристаллы человеческого гормона роста и способы их получения
EP1595549A4 (en) 2003-02-19 2010-09-22 Takeda Pharmaceutical DISPERSE FOR PREPARATIONS WITH DELAYED RELEASE
JP4683319B2 (ja) 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
CN1245510C (zh) 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
CN1243022C (zh) 2003-10-17 2006-02-22 华东师范大学 生物修饰重组人生长激素复合物及其制备方法
US7649084B2 (en) 2003-11-12 2010-01-19 University Of Georgia Research Foundation, Inc. Recombinant glycoproteins related to feline thyrotropin
SI1696947T1 (sl) 2003-12-19 2014-05-30 F. Hoffmann-La Roche Ag Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih
EP1755652B1 (en) 2004-03-19 2010-11-24 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
CA2585507A1 (en) 2004-09-27 2006-04-06 Cornell Research Foundation, Inc. Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin b-subunit and uses thereof
EP2371390A3 (en) 2004-10-08 2013-03-13 Domantis Limited Antagonists and methods of use therefor
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
WO2007047834A2 (en) 2005-10-18 2007-04-26 Biocon Limited Oral peptide conjugates for metabolic diseases
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP4660783B2 (ja) 2006-05-15 2011-03-30 末雄 町田 頬スリム器具
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
DE102007006189B4 (de) 2007-02-07 2009-07-30 Isotopen Technologien München AG Vorrichtung zum Befüllen eines medizinischen Instruments mit einer radioaktiven Substanz und Verfahren
AT505262A1 (de) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
CA2707796A1 (en) 2007-12-05 2009-08-27 Novozymes A/S Polypeptides having endoglucanase activity and polynucleotides encoding same
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CN102413990A (zh) 2009-02-27 2012-04-11 钴领无限公司 模块化自动工具配送机
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
DE102009031992A1 (de) 2009-07-06 2011-01-13 Paul Hartmann Ag Vorrichtung zur Unterdrucktherapie von Wunden
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR102092206B1 (ko) 2011-06-02 2020-03-24 옵코 바이오로직스 리미티드 장기-작용성 glp-1/글루카곤 수용체 작용제
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
RU2607365C2 (ru) 2011-06-17 2017-01-10 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
JP5901300B2 (ja) 2012-01-13 2016-04-06 キヤノン株式会社 画像形成装置
PL3791890T3 (pl) * 2012-02-14 2025-04-14 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i ich zastosowania
HK1207564A1 (en) 2012-04-19 2016-02-05 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
EA201492269A1 (ru) 2012-06-04 2016-02-29 Опко Байолоджикс Лтд. Пегилированные варианты oxm
HUE055348T2 (hu) 2012-11-20 2021-11-29 Opko Biologics Ltd Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3230309B1 (en) 2014-12-10 2023-03-29 OPKO Biologics Ltd. Methods of producing long acting ctp-modified growth hormone polypeptides
JP6380209B2 (ja) 2015-03-31 2018-08-29 ブラザー工業株式会社 画像処理プログラム、画像処理装置、及び、画像処理方法
KR20180014754A (ko) 2015-05-29 2018-02-09 옵코 바이오로직스 리미티드 페길화된 옥신토모둘린 변이체
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania

Also Published As

Publication number Publication date
US20220000990A1 (en) 2022-01-06
HUE055449T2 (hu) 2021-11-29
KR102172937B1 (ko) 2020-11-03
AU2016280867B2 (en) 2020-02-27
JP2023022213A (ja) 2023-02-14
JP2018520132A (ja) 2018-07-26
IL256374A (en) 2018-02-28
AU2022204726B2 (en) 2025-05-29
EP3310347B1 (en) 2021-08-04
IL288556B2 (en) 2023-08-01
CA2989990A1 (en) 2016-12-22
IL288556B1 (en) 2023-04-01
CN113289009B (zh) 2025-05-02
WO2016203482A3 (en) 2017-03-09
ES2893616T3 (es) 2022-02-09
EP3310347A4 (en) 2019-02-06
KR20220166363A (ko) 2022-12-16
AU2022204726A1 (en) 2022-07-21
AU2020203459A1 (en) 2020-08-13
HK1254382A1 (zh) 2019-07-19
US20180360932A1 (en) 2018-12-20
AU2020203459B2 (en) 2022-03-31
IL288556A (en) 2022-02-01
JP2020164545A (ja) 2020-10-08
WO2016203482A2 (en) 2016-12-22
CN108289851B (zh) 2021-06-01
EP3310347A2 (en) 2018-04-25
KR20200128753A (ko) 2020-11-16
CN113289009A (zh) 2021-08-24
JP7187505B2 (ja) 2022-12-12
KR102662956B1 (ko) 2024-05-03
US10960058B2 (en) 2021-03-30
KR102473014B1 (ko) 2022-11-30
CA2989990C (en) 2024-03-12
JP7680996B2 (ja) 2025-05-21
CA3228939A1 (en) 2016-12-22
EP3988113A1 (en) 2022-04-27
KR20180030542A (ko) 2018-03-23
JP7096668B2 (ja) 2022-07-06
CN108289851A (zh) 2018-07-17
IL301728A (en) 2023-05-01
AU2016280867A1 (en) 2018-02-01
IL256374B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
IL288556B1 (en) Long-term coagulation factors and methods for their preparation
IL286316A (en) New micro-dystrophins and related method of use
SG11201606575TA (en) Method of producing polyethylene and polyethylene thereof
GB201513461D0 (en) Methods and devices for the production of decellularised tissue scaffolds
EP3116851A4 (en) Analogs of fexaramine and methods of making and using
AU2015287923B2 (en) Hollow metalscrew and method of making
EP3107879A4 (en) Superconducting wires and methods of making thereof
GB201507188D0 (en) Resilient unit and method of manufacture
EP3303571A4 (en) Live-attenuated virus and methods of production and use
GB2522719B (en) Method of manufacture
GB2528136B (en) User-adjustable headband and method of manufacture thereof
SG10202102552RA (en) Adsorbents and methods of making and using adsorbents
GB2544343B (en) Receptacle and its method of manufacture
IL264208A (en) Long-term coagulation factors and methods for their preparation
ZA201800709B (en) Processable polymers and methods of making and using thereof
GB2522716B (en) Method of manufacture
GB201509023D0 (en) Compositions and methods of production thereof
HRP20180655T1 (hr) Vijak i postupak njegove proizvodnje
GB201408171D0 (en) Formulation and method of manufacture
EP3370860A4 (en) METHOD FOR PRODUCING HETERODIAMANTS AND DEVICE THEREFOR
IL246493A0 (en) tool and method to produce it
GB201517863D0 (en) Polymers and methods of their production
GB201419990D0 (en) Hprseshoe and method of manufacture
GB201520043D0 (en) Needle assemblies and methods of manufacture
GB201417782D0 (en) Polymers and methods of their Production